[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Risks and benefits with Professor Fenton", "description": "Relative risk versus absolute risk with Professor Norman Fenton, Mathematician, Professor of Risk Information Management\n\nProfessor Fenton, YouTube channel\n\nhttp://youtube.com/@normanfenton81\n\nAnd Sub stack\n\nhttps://wherearethenumbers.substack.com/\nnormanfenton.com\n\nLink to video on Norman's channel\nhttps://www.youtube.com/watch?v=Va9aE98cFCA\n\nDownload the slides used in this video\nhttps://d7694293-ffb8-4ed0-a014-3581d49070e4.usrfiles.com/ugd/d76942_9aec73e0e123495dba17f070437aadc8.pdf\n \nNor\nWhat is risk information management?\n\nThinking about risk, what do we mean by absolute risk and relative risk\n\nSounds a bit like the level of risk can be presented in a way that gives a particular impression of a greater or a lessor risk or benefit?\n\nAre there occasions when a vested interest might want to give an impression of an increased benefit, or reduced risk from an intervention?\n\nHow could choosing RRR versus ARR influence the impression given for adverse reactions is medical journals?\n\nConversely\n\nAre there occasions when a vested interest might want to give an impression of a decreased risk from an intervention?\n\nSo will RRR always be higher than ARR?\n\nWhy can the RRR vary between populations and vary over time?\n\nSo using one of the two measures to estimate the risk/benefit ratio would lead to different conclusions?\n\nHow could risk / benefit reporting be optimised in the medical literature?\n\nDo you think the editors of prestigious international journals are aware of the differences between RRR and ARR?\n\nIn the case of this paper from the Journal of Expert Reviews of Vaccines\n\nEfficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115787/\n\nThe original phase three data gave an efficacy for Pfizer vaccine, at preventing infection with SARS-CoV-2 of 95%, but it turns out the ARR was 0.84%\n\nWhy are these figures so different?\n\nSo is it fair to say that the \u2018real world translation\u2019 of the ARR of the Pfizer vaccine over 5 to 6 months of use increased to 3.7%?\n\nWhat do we mean by number needed to treat?", "link": "https://www.youtube.com/watch?v=fgVpVHL8nkY", "date_published": "2022-12-12 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Chinese vaccine comparisons", "description": "Chinese and Western vaccines compared\n\nhttps://www.bbc.co.uk/news/world-asia-china-63855508\n\nBig changes, all of a sudden\n\nLive with the virus\n\nVice-premier, Sun Chunlan\n\nChina entering a new situation\n\nVirus ability to cause disease weakening\n\nLifting most severe Covid policies\n\nEnd of quarantine camps\n\nPeople can isolate at home\n\nNo more family separations\n\nClose contacts not taken to camps\n\nStrict ban on blocking fire exits\n\nNo need to show tests for venues\n\nLess rules on internal travel\n\nLateral flow tests to replace PCR tests in most areas\n\nLockdowns continue in smaller more targeted areas\n\nForeign travel soon\n\nCases, 30,000 +\n\nNow\n\nEveryone will be exposed\n\nWill the medical system will be overwhelmed?\n\nNational Health Commission\n\nAll localities, focus on improving the vaccination rate of people aged 60-79, \n\naccelerating the vaccination rate of people aged 80 and above, \n\nand making special arrangements\n\nProf Ivan Hung, Hong Kong University\n\nThe main way for China to exit Covid with the least damage is via vaccination and three doses of vaccination is a must\n\nHopefully before Chinese New Year (January 22) Rabbit\n\nSinopharm\n\nStrategic Advisory Group of Experts on Immunization (SAGE)\n\nhttps://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know\n\nThe vaccine is safe and effective for all individuals aged 18 and above. \n\nIndividuals may choose to delay vaccination for 3 months following the infection.\n\nAn inactivated vaccine with adjuvant\n\n(that is routinely used in many other vaccines)\n\nwith a documented good safety profile, including in pregnant women. \n\nSymptomatic SARS-CoV-2 infection and efficacy against hospitalization 79%\n\nDoes it prevent infection and transmission?\n\nNo substantive data\n\nDoes it work against new variants of SARS-\nCoV-2 virus?\n\nSAGE currently recommends using this vaccine\n\nNot yet been evaluated in the context of circulation of widespread variants of concern.\n\nHow does this vaccine compare to other vaccines already in use?\n\nWe cannot compare the vaccines head-to-head,\n\n(different approaches taken in designing the respective studies)\n\nbut overall, all of the vaccines that have achieved WHO Emergency Use Listing,\n\nare highly effective in preventing severe disease and hospitalization due to COVID-19.\n\nComparison with Western vaccines\n\nPfizer original paper\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2034577\n\nhttps://www.nejm.org/doi/suppl/10.1056/NEJMoa2034577/suppl_file/nejmoa2034577_appendix.pdf\n\nBNT162b2 was 95% effective in preventing Covid-19\n\nLater analysis from \n\nEfficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115787/\n\nAAR, Pfizer, during the trial period,\n\n0.84%\n\nAAR\n\nhttps://patient.info/news-and-features/calculating-absolute-risk-and-relative-risk\n\nAbsolute risk of a disease is your risk of developing the disease over a time period. \n\nFive to six-months update, AAR\n\nBNT162b2  3.7%\n\nmRNA1273 (Moderna-NIH)  4.9%", "link": "https://www.youtube.com/watch?v=MN315cA3Aaw", "date_published": "2022-12-11 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]